Physiomics secures contract with Numab Therapeutics

Physiomics noted it has "recent significant experience" in the mathematical modelling of multi-specific pharmaceuticals, which it will use to work on an undisclosed compound as part of Numab's project, which was expected to last "around three months".

The AIM-listed group added that Numab was an "exciting young biopharmaceutical company" based in Zurich, Switzerland which develops "multi-specific biotherapeutics" for chronic inflammation and cancer.

Chief executive Dr Jim Millen said: "We are delighted that Numab has selected Physiomics to support them with one of their new programs and look forward to working with their highly talented team."

As of 1045 BST, Physiomics shares were up 2.56% at 6.0p.